Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Cambridge University Hospitals NHS Foundation Trust
OBJECTIVES: Primary * To compare the efficacy of neoadjuvant therapy comprising docetaxel, fluorouracil, epirubicin hydrochloride, and cyclophosphamide with versus without bevacizumab in patients with HER2-negative nonmetastatic breast cancer. Secondary * To assess quality of life of female patients treated with these regimens. OUTLINE: This is a multicenter study. Patients are stratified according to age (≤ 50 years old vs \> 50 years old), estrogen receptor status (negative \[Allred score 0-2\] vs weakly positive \[Allred score 3-5\] vs strongly positive \[Allred score 6-8\]), total tumor size\* (≤ 50 mm vs \> 50 mm), clinical involvement of axillary nodes (yes vs no), and inflammatory/locally advanced disease (T4) (yes vs no). Patients are randomized to 1 of 2 treatment arms. NOTE: \*In cases with multifocal disease in one breast, or bilateral disease, the size to be used for the stratification is the sum of the single largest diameter of all measurable tumors. * Arm I: Patients receive docetaxel IV on day 1; treatment repeats every 3 weeks for 3 courses. Patients then receive fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1 (FEC). Treatment with fluorouracil, epirubicin hydrochloride, and cyclophosphamide repeats every 3 weeks for 3 courses. * Arm II: Patients receive bevacizumab IV over 30 to 90 minutes and docetaxel IV on day 1; treatment repeats every 3 weeks for 3 courses. Patients then receive FEC as in arm I. Treatment with FEC repeats every 3 weeks for 3 courses. Patients also receive bevacizumab IV over 30 to 90 minutes and docetaxel IV on day 1 in FEC course 1 only. Within 3-6 weeks after completion of last dose of study therapy, patients in both arms undergo surgery. Within 4-8 weeks after surgery, patients undergo radiotherapy according to standard protocol. Women complete quality-of-life questionnaires (FACT-B and EuroQoL) at baseline and during and after completion of study treatment. After completion of study treatment, patients are followed every 6 months for 2 years and then annually for 3 years.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
